- Home
- SFHG vs TSHA Comparison
SFHG vs TSHA Comparison
Compare SFHG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFHG | TSHA |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 1.2B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFHG | TSHA |
|---|---|---|
| Price | $0.67 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 631.5K | ★ 3.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,577,200.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $0.32 | $1.05 |
| 52 Week High | $2.32 | $5.95 |
Technical Indicators
Market Signals| Indicator | SFHG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 73.22 | 67.47 |
| Support Level | $0.55 | $5.22 |
| Resistance Level | $0.59 | $5.54 |
| Average True Range (ATR) | 0.07 | 0.32 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 97.27 | 92.43 |
Price Performance
Historical ComparisonAbout SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.